Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis (vol 42, pg 75, 2022)

被引：0
|
作者：
Razmjou, Amir A. [1 ]
Wang, Jennifer M. [1 ]
Shahbazian, Ani [1 ]
Reddy, Srinivasa [1 ]
Charles-Schoeman, Christina [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, 1000 Vet Ave,Room 31-79, Los Angeles, CA 90095 USA
来源：
CLINICAL RHEUMATOLOGY | 2023年 / 42卷 / 11期
关键词：
D O I：
10.1007/s10067-023-06768-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3175 / 3175
页数：1
相关论文
共 9 条
  • [1] Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis
    Amir A. Razmjou
    Jennifer M. Wang
    Ani Shahbazian
    Srinivasa Reddy
    Christina Charles-Schoeman
    Clinical Rheumatology, 2023, 42 : 75 - 82
  • [2] Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis
    Razmjou, Amir A.
    Wang, Jennifer M.
    Shahbazian, Ani
    Reddy, Srinivasa
    Charles-Schoeman, Christina
    CLINICAL RHEUMATOLOGY, 2023, 42 (01) : 75 - 82
  • [3] Correction to: Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis
    Amir A. Razmjou
    Jennifer M. Wang
    Ani Shahbazian
    Srinivasa Reddy
    Christina Charles-Schoeman
    Clinical Rheumatology, 2023, 42 : 3175 - 3175
  • [4] Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
    Razmjou, Amir
    Wang, Jennifer
    Shahbazian, Ani
    Reddy, Srinivasa
    Charles-Schoeman, Christina
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 593 - 596
  • [5] Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins
    Razmjou, Amir A.
    Kremer, Joel M.
    Pappas, Dimitrios A.
    Curtis, Jeffrey R.
    Wang, Jennifer
    Shahbazian, Ani
    Elashoff, David A.
    Guo, Rong
    Meriwether, David
    Sulaiman, Dawoud
    O'Connor, Ellen
    Reddy, Srinivasa T.
    Charles-Schoeman, Christina
    RMD OPEN, 2024, 10 (04):
  • [6] Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
    Razmjou, Amir
    Wang, Jennifer
    Shahbazian, Ani
    Curtis, Jeffrey
    Pappas, Dimitrios
    Kremer, Joel
    Charles-Schoeman, Christina
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4402 - 4404
  • [7] Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study (vol 42, pg 599, 2015)
    Takeuchi, T.
    Miyasaka, N.
    Inui, T.
    Yano, T.
    Yoshinari, T.
    Abe, T.
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (05)
  • [8] Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study (vol 42, pg 599, 2015)
    Takeuchi, T.
    Miyasaka, N.
    Inui, T.
    Yano, T.
    Yoshinari, T.
    Abe, T.
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (04)
  • [9] Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial (vol 1, pg e23, 2019)
    Cohen, S. B.
    Pope, J.
    Haraoui, B.
    LANCET RHEUMATOLOGY, 2019, 1 (04): : E205 - E205
1